On Wednesday, Following Stocks were among the “Top 50 Gainers” of U.S. Stock Market: Odyssey Marine Exploration Inc (NASDAQ:OMEX), Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY), California Resources Corp (NYSE:CRC), Magnum Hunter Resources Corp (NYSE:MHR)
Odyssey Marine Exploration Inc (NASDAQ:OMEX), with shares inclined 9.55%, closed at $0.600.
Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY), with shares jumped 9.78%, settled at $0.780.
California Resources Corp (NYSE:CRC), with shares climbed 8.92%, and closed at $7.08.
Magnum Hunter Resources Corp (NYSE:MHR), surged 8.92%, and closed at $2.32.
Latest NEWS regarding these Stocks are depicted underneath:
Odyssey Marine Exploration Inc. (NASDAQ:OMEX)
Formerly on March 13, Odyssey Marine Exploration Inc. (OMEX), a pioneer in the field of deep-ocean exploration, declared the signing of a planned financing contract with Minera del Norte S.A. de c.v. (MINOSA), an owner and operator of mines and mineral rights (with worldwide assets of more than $750 million and net sales of $900 million) to facilitate Odyssey’s offshore mineral and resource exploration. Under the contract, MINOSA will extend short-term, debt financing to Odyssey of up to $14.75 million. In addition, Penelope Mining LLC, a wholly-owned partner of MINOSA, has agreed to invest up to $101 million over three years in convertible preferred stock of Odyssey. The debt and the equity financings are subject to the satisfaction of certain conditions counting those described below under “Financing Terms.”
Mark Gordon, President and CEO of Odyssey commented that, “The debt financing will enable us to continue our ongoing operations, and the equity financing will assist position us to dramatically advance our business of locating and recovering assets on the sea floor and to enhance our potential to deliver substantial value to stockholders.”
Odyssey Marine Exploration, Inc., together with its auxiliaries, is engaged in the archaeologically sensitive exploration and recovery of deep-ocean shipwrecks worldwide. The corporation has discovered hundreds of shipwrecks ranging from fifth-century BC Punic sites to German U-boats and Colonial warships. In 2012 and 2013 the corporation set a world record for the deepest shipwreck cargo recovery with 110 tons of silver recovered from the SS Gairsoppa nearly 4,700 meters deep.
Oncolytics Biotech Inc. (NASDAQ:ONCY)
On Monday, Oncolytics Biotech Inc. (ONCY), declared its financial results and operational highlights for the year ended December 31, 2014.
Since January 1, 2014, selected highlights declared by the Corporation comprise:
Clinical Program:
Completion of patient enrollment in an ongoing, NCIC Clinical Trials Group sponsored randomized Phase II study of REOLYSIN® in patients with advanced or metastatic colorectal cancer (IND 210). The Corporation awaits preliminary data from this study;
Reporting completion of enrollment and interim overall and KRAS-mutated patient data from an NCI-sponsored randomized Phase II study of REOLYSIN® in combination with carboplatin and paclitaxel in patients with recurrent or metastatic pancreatic cancer (NCI-8601). The Corporation awaits final data from this study, which will be accessible once all remaining patients have progressed;
Completion of patient enrollment in an ongoing, NCI-sponsored randomized Phase II study of REOLYSIN® in combination with paclitaxel in patients with persistent or recurrent ovarian, fallopian tube or primary peritoneal cancer (GOG-186H). The Corporation awaits preliminary data from this study;
Reporting final data from the Corporation’s randomized, double-blinded clinical study examining REOLYSIN® in combination with carboplatin and paclitaxel in patients with second-line, platinum-refractory, taxane-naïve head and neck cancers;
Presentation by the Corporation’s collaborators of preliminary clinical data demonstrating that intravenously delivered REOLYSIN® can cross the blood brain barrier to access tumours in the brains of humans;
Regulatory:
Application for Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for REOLYSIN® in the treatment of ovarian and pancreatic cancers. The Corporation was granted designations in ovarian, fallopian tube, primary peritoneal and pancreatic cancer subsequent to year end;
Application to the European Medicines Agency for Orphan Designation for REOLYSIN® in the treatment of pancreatic and ovarian cancers;
Subsequent to year end, the Corporation applied to the U.S. FDA for a fifth Orphan Drug Designation for high grade gliomas in paediatric patients.
Basic Research:
Presentation of a poster entitled “Combination Therapy with Reovirus and PD-1 Blockade Effectively Establishes Tumour Control Via Innate and Adaptive Immune Responses” by the Corporation’s research collaborators, Vile et al., at the AACR Tumor Immunology and Immunotherapy Conference;
A series of presentations made by the Corporation’s research collaborators at the 8th Annual International Conference on Oncolytic Virus Therapeutics held in Oxford, UK, covering:
Preclinical research examining the synergies associated with treatment in animal models with GM-CSF preceding to administering REOLYSIN®;
Preclinical research focused on identifying biomarkers predictive of sensitivity/resistance to reovirus in head and neck cancer cell lines; and
Preclinical research into the treatment of hepatocellular carcinoma associated with infection by Hepatitis B and Hepatitis C.
Oncolytics Biotech Inc., a development stage biopharmaceutical corporation, focuses on the discovery and development of pharmaceutical products for the treatment of cancers. The corporation develops REOLYSIN, a therapeutic reovirus that is in various clinical trials for use as human cancer therapeutic. Its cancer product is a potential therapeutic for tumours possessing an activated Ras pathway. The corporation was founded in 1998 and is headquartered in Calgary, Canada.
California Resources Corporation (NYSE:CRC)
Formerly on February 26, California Resources Corporation (CRC), declared that its Board of Directors has approved its first quarterly dividend of 1 cent per share, payable April 15, 2015 to stockholders of record at the close of business on March 10, 2015. The current annualized rate would be $0.04 per share.
California Resources Corporation operates as an oil and natural gas exploration and production corporation in the State of California. It produces oil, natural gas, and natural gas liquids. The corporation holds interests in about 2.4 million net acres. It also gathers, processes, and markets oil and gas products, in addition to produces and sells power. The corporation is headquartered in Los Angeles, California.
Magnum Hunter Resources Corp. (NYSE:MHR)
On Monday, Eureka Hunter Pipeline, LLC, in which a Magnum Hunter Resources Corp. (MHR), owns a substantial equity interest, declared that throughput volumes on Eureka Hunter’s gas gathering pipeline system located in West Virginia and Ohio, have now reached a new record of about 623,713 MMBtu per day on Friday, March 13, 2015.
Magnum Hunter Resources Corporation, an independent oil and gas corporation, explores for, exploits, attains, develops, and produces crude oil, natural gas, and natural gas liquid resources in the United States.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
